Helping the World Breathe Easier™
Developing New Prescription Cough Medicines
Committed to Finding Solutions for the SARS-CoV-2 Pandemic
Respiratory Orphan Drug Strategy
Partnering and Licensing to Unlock Value
Moving Towards Safer Prescription Drug Dosing
Alitair Pharmaceuticals is dedicated to collaborating with best in class strategic partners to develop therapies to address unmet medical need
We are seeking innovative partnerships to collaborate on developing and commercializing new therapies based on the Alitair Pharmaceuticals Orphan Drug portfolio and our unique formulation-based IP that will allow us to best meet patient needs in the respiratory disease therapeutic area. Key therapeutic priority areas are:
Non-narcotic prescription cough medicines
Bronchiectasis treatments in the Non-Cystic Fibrosis and Cystic Fibrosis patient populations
We are also actively looking at opportunities to study our compounds in response to SARS-CoV-2 / COVID-19. See our “News” section for more details.
We look to build long-term relationships with companies who want to partner with Alitair on this important endeavor to serve patients and providers while building value for all partner stakeholders.
Call us to discuss collaboration opportunities.
